The Wegovy maker’s once-daily pill to treat type 2 diabetes has shown it cuts the risk of heart attacks and strokes in ...

Novo Nordisk faces competition from Eli Lilly in new therapeutic areas. Read why I rate NONOF stock as a hold.

A Watertown biotech says is received a $112 million investment led by the investment firm that manages the assets of the Novo ...

The pill version of Novo Nordisk’s (NVO) blockbuster drug Ozempic was found to cut the risk of heart attacks, strokes, and ...

As Novo Nordisk’s injectable diabetes-obesity duo Ozempic and Wegovy grab all the limelight, an oral version of the ...

The Wegovy makers’s once-daily pill to treat type 2 diabetes has shown it cuts the risk of heart attacks and strokes in ...

Novo Nordisk faces growth deceleration but shows promise. Learn more about NVO stock and why its risk/reward profile may ...

A study found that prescriptions for GIP/GLP-1 RA drugs may reduce opioid overdose and alcohol intoxication rates in patients ...

For the first time in a decade, the American Heart Association and American Stroke Association issued new recommendations for ...

On Monday, Novo Nordisk A/S (NYSE:NVO) released the headline results from the SOUL Phase 3 cardiovascular outcomes trial.

Earlier this year, J.P. Morgan released a report outlining the potential for GLP-1 treatments in other markets. Specifically, ...

WEIGHT-LOSS jabs are the most talked about drugs of the moment. And with new studies popping up almost every week revealing ...